Logotype for Voya Financial Inc

Voya Financial (VOYA) Q2 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Voya Financial Inc

Q2 2024 earnings summary

2 Feb, 2026

Executive summary

  • Net income available to common shareholders rose to $201 million ($1.96 per diluted share) for Q2 2024, up from $154 million ($1.41 per diluted share) in Q2 2023, driven by investment gains and lower integration costs.

  • Adjusted operating EPS was $2.18, with strong fee-based revenue growth in Wealth and Investment Management offsetting higher loss ratios in Health Solutions.

  • On track to meet full-year 2024 EPS target of $8.25–$8.45, supported by revenue growth, spend control, and commercial momentum.

  • Increased quarterly dividend by 12.5% to $0.45 per share, reflecting robust capital generation and confidence in sustainable growth.

  • Wealth and Investment Management outpaced net revenue growth targets, while Health Solutions faced higher loss ratios but is taking repricing actions.

Financial highlights

  • Q2 2024 net income was $201 million, up from $154 million year-over-year, reflecting investment gains and lower integration costs.

  • Adjusted operating earnings were $223 million ($2.18 per share), down from $243 million ($2.21 per share) year-over-year, mainly due to lower Health Solutions underwriting gains.

  • Wealth Solutions adjusted operating earnings reached $214 million, up year-over-year due to strong fees and expense discipline.

  • Health Solutions adjusted operating earnings declined to $60 million, impacted by higher loss ratios despite 16% premium growth.

  • Investment Management adjusted operating earnings were $50 million, with net inflows of $4.8 billion and margin improvement.

Outlook and guidance

  • Full-year adjusted operating EPS guidance reaffirmed at $8.25–$8.45, assuming long-term alternative investment return of 9%.

  • On track to generate $0.8 billion of excess capital and achieve 2–4% net revenue growth, 30–33% adjusted operating margin, and 14–16% ROE for FY'24.

  • Health Solutions FY'24 aggregate loss ratio expected to be above the 69–72% range; repricing actions underway to improve 2025 results.

  • Investment Management targeting 2% organic net flow growth for FY'24, supported by strong net inflows and new fund launches.

  • Management expects continued growth in adjusted operating EPS through net revenue growth, margin expansion, and disciplined capital management.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more